Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5083945 + cisplatin + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RO5083945 + cisplatin + gemcitabine is an investigational combination regimen in oncology trials, primarily developed for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC) of squamous histology. RO5083945 (also known as GA201) is a glycoengineered, human monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR). It antagonizes EGFR by binding and blocking ligand-induced activation, and it is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) via increased binding to FcγRIIIa on immune effector cells, improving tumor cell killing compared to other anti-EGFR mAbs like cetuximab. Cisplatin is a platinum-based chemotherapeutic agent that kills cancer cells by cross-linking DNA, and gemcitabine is a nucleoside analog chemotherapy that inhibits DNA synthesis[3][4].
- Other names
- huMab<EGFR> (GA201)
02
Targets
Beyond the preview
Go deeper on RO5083945 + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5083945 + cisplatin + gemcitabine.